>>Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder
Thursday March 5, 2009, 5:30 pm EST
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 440-patient study evaluating the efficacy and safety of SEP-225441, a modified-release formulation of eszopiclone for the treatment of generalized anxiety disorder (GAD). Sepracor determined that the study did not meet its primary efficacy endpoint, which was reduction in symptoms of GAD, as assessed using the clinician-rated HAM-A scale (Hamilton Anxiety Rating Scale, a standard scale used to assess anxiety in clinical trials and consisting of a list of symptoms commonly associated with anxiety).
“While we are disappointed with the preliminary analysis of the study results, we are in the process of further analyzing the data in an effort to determine whether any of the secondary endpoints were met and whether this compound warrants further clinical development,” said Mark H.N. Corrigan, M.D., Executive Vice President, Research and Development of Sepracor.<<
snip
So one can hope this GABA-A receptor alpha2/3 agonist does better. SEPR off a bit extra after hours, but not that much; I would guess not much was expected of Lunesta for GAD. I know I wouldn't expect much.
Cheers, Tuck |
